ExodusPoint Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

ExodusPoint Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$63.4K	Buy	+16,895	New	+$57K	﹤0.01%	1455
2025 Q2	–	Sell	-59,865	Closed	-$92K	–	1417
2025 Q1	$92K	Buy	59,865 +49,228	+463%	+$105K	﹤0.01%	1349
2024 Q4	$26K	Buy	+10,637	New	+$26.5K	﹤0.01%	1433
2023 Q4	–	Sell	-146,454	Closed	-$1M	–	1406
2023 Q3	$1M	Buy	+146,454	New	+$1.25M	0.01%	969
2023 Q1	–	Sell	-14,753	Closed	-$232K	–	1704
2022 Q4	$232K	Buy	+14,753	New	+$237K	﹤0.01%	1421
2021 Q3	–	Sell	-28,975	Closed	-$509K	–	2036
2021 Q2	$509K	Sell	28,975 -111,880	-79%	-$2.54M	0.01%	1385
2021 Q1	$3.55M	Sell	140,855 -81,793	-37%	-$1.6M	0.05%	377
2020 Q4	$1.44M	Buy	+222,648	New	+$939K	0.01%	684

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ExodusPoint Capital Management's ACRS Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 16,895 shares worth $63.4K. The stake represents ﹤0.01% of the portfolio and ranks #1455 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in ACRS as recently as Q1 2025.

ExodusPoint Capital Management first reported a position in ACRS in Q4 2020 and has held it in 8 quarters since. The position peaked at $3.55M in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

ExodusPoint Capital Management held 16,895 shares of Aclaris Therapeutics worth $63.4K as of Q1 2026.
Aclaris Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
Aclaris Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1455 holding.
ExodusPoint Capital Management first reported a position in Aclaris Therapeutics in Q4 2020 and has held it in 8 quarters since.
ExodusPoint Capital Management's Aclaris Therapeutics position peaked at $3.55M in Q1 2021.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.